Aligos Therapeutics, Inc. (ALGS): Cash & Equivalents
$18.30M
As of 2025-12-31
$30.38M
As of 2026-06-30
-39.2%
3-year compound annual growth
-39.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.30M | -50.5% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $37.00M | -72.7% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $135.70M | +66.8% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $81.35M | -56.5% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $186.82M | -15.2% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $220.38M | +216.8% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $69.56M | n/a | 2021-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $18.30M | -50.5% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $4.62M | -29.0% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $8.08M | -45.9% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $89.25M | +158.2% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $347.56M | +16.5% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.66M | -15.4% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $124.22M | -18.6% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $32.49M | -87.4% |
Compare ALGS, HUMA, DYAI, OTLK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗